The two-time defending champion Texas Longhorns are out of the NCAA women's volleyball tournament, eliminated 3-1 Friday in the regional semifinals by Creighton in State College, Pennsylvania. It wasn't an upset in terms of seeding, as the Bluejays are the No. 2 seed and Texas is No. 3 in the Penn State regional. But Texas is a four-time national champion and one of the sport's longtime powerhouses. Creighton has never made it to the final four but will have the chance to do so in Sunday's regional final against either No. 1 seed Penn State or No. 5 Marquette. This is Creighton's second appearance in a regional final; the Bluejays advanced in 2016 but were eliminated by Texas. On Friday, Creighton won its 25th match in a row, the longest active streak in Division I. Norah Sis led Creighton with 15 kills, 3 blocks and 13 digs. Editor's Picks NCAA volleyball tournament: 16 players to watch in regionals 1d Aishwarya Kumar and Michael Voepel Pitt volleyball chases history with a hunter's mindset 8d Aishwarya Kumar Creighton men's basketball coach Greg McDermott posted on social media that his team stopped practice to watch the clinching point of the volleyball match and to celebrate the Bluejays victory. Texas' quest to become the second Division I women's volleyball team to win three NCAA titles in a row came to an end. The only school to do that is Penn State, which won four consecutive titles from 2007-10. Madisen Skinner, who has won NCAA titles at Kentucky and Texas, led the Longhorns with 23 kills Friday. Texas won NCAA championships in 1988, 2012, 2022 and 2023, plus has gone to the NCAA final four 11 other times. The Longhorns started this season ranked No. 1 in the AVCA top 25 poll, but ran into some tough times right away, losing three of their first six matches. In its first season in the SEC, Texas went 13-3, finishing second to league champion Kentucky. The Wildcats advanced Thursday to the Pittsburgh regional final, where they will face host Pitt, the No. 1 overall seed, Saturday (ESPN2, 5 p.m. ET) for a trip to the final four. Saturday's other regional final is at Louisville, where the No. 1 seed Cardinals host No. 2 Stanford (ESPN2, 7:30 p.m. ET). Sunday's regional finals will be held at Penn State and Nebraska. The final four is in Louisville, with the semifinals on Dec. 19 at 6:30 and 9:30 p.m. ET on ESPN and the final on Dec. 22 at 3 p.m. ET on ABC.

Nicolette Boele ‘gave up’ on politics over Labor’s climate inaction. Now she wants to win a Liberal seatHis former co-star, DeMar DeRozan, is gone . The bottom fell out of the defense with the departure of Alex Caruso . The best way to build up his trade value is to stockpile stat sheets to convince other teams of his viability on a contender. And in a Chicago Bulls season already written off as a must-lose for better draft positioning, it wouldn’t have been surprising — or even upsetting — if LaVine had chosen to soak up as much of the spotlight as possible. But that isn’t the case. LaVine is back to his old-school heroics, slinging 3-pointers and throwing down splashy dunks over the heads of his defenders. And he’s doing it more efficiently — and with less frustration — than ever. “I can be a star in whatever situation I’m in,” LaVine told the Tribune. “I’m still super effective — and I’m going to keep it that way. I understand what I have to do for the team. I’ve tried to really embrace and accept that role, whether that’s taking the challenge defensively, being a facilitator or even fitting into a role, helping guys out and then asserting myself when I need to.” For most of his tenure, the Bulls often fell back on LaVine out of desperation. When the offense ground to a halt or the 3-pointers weren’t falling, the Bulls looked to their star — or, as LaVine described it, “OK, why don’t we just let Zach shoot it 28 times?” This season is different. LaVine is averaging the lowest usage (24.2%) of his eight-year tenure with the Bulls (excluding last season, when he played only 25 games due to injury). This means that for the first time since his second season in the league, LaVine is not ending a play — either by taking a shot, drawing a foul or turning the ball over — for more than 75% of the time he is on the court. His teammates are quick to reassure that it’s not from a lack of belief in LaVine. “Everybody knows Zach LaVine can go out there and get you 30 points whenever he wants,” guard Coby White said. But in a higher-paced offense that values 3-point shots above all else, LaVine has more flexibility to spread the ball. He’s taking 15.5 shots per game, a notable decline from his average of 18 in the 2022-23 season and his career high of 20 in 2019-20. Despite the decline in volume, the Bulls average 11.7 more points per 100 minutes with LaVine on the court. “I’m picking my spots better this year,” Lavine said. “You want to have everybody have a rhythm. If I need to come out aggressive, I should do that, but you don’t want to have guys not touch the ball until the third quarter when it really matters.” Monday’s win over the Detroit Pistons encapsulated LaVine’s new approach. At the start, he was just looking to get teammates involved, logging five assists and only eight shots in the first half. But once his first 3-pointer dropped in the fourth, a switch flipped. LaVine sank a trio of 3s in 61 seconds, ripping off 18 of his 25 points in the quarter. White described that win as a “perfect” game for LaVine in Year 11. And for teammates such as fourth-year guard Ayo Dosunmu aiming to make a major leap in their progress, the balance LaVine is striking has provided a significant confidence boost. “Him being that big bro, that big vet, he’s really allowing everyone to come out and contribute and thrive and play at their best,” Dosunmu said. “And he’s still Zach LaVine. He’s still able to take over any game. But I think it’s making him harder to guard because he’s not so ball dominant, but he’s still so effective. That’s just a credit to him. Ultimately, whenever we need him, he’s always there.” LaVine wasn’t happy last season. That much was obvious. Nothing was going right for the Bulls. So LaVine let himself get angry. Over the criticism from fans sparked by reports of his attempt to push a trade out of Chicago. Over the complicated fracture in his right foot that hindered every step on the court. Over the losses — and sometimes even after the wins. But something shifted after the birth of his second son, Elijah, in March. Fatherhood already had a reframing effect on LaVine when his elder son, Saint, was born in 2022 . But raising two boys was a new challenge — a joyful one — that shook him out of the funk that plagued him for the 2023-24 season. At that point, he had been away from the Bulls for a full month, rehabbing from foot surgery in California while preparing for Elijah’s birth with his wife, Hunter. And as he juggled parenthood with recovery and preparation to return to Chicago, LaVine said he realized there simply wasn’t enough time in the day to linger in his frustration. “When you’re upset or mad about things, you don’t have a clear train of thought,” LaVine said. “As a parent now of two, I can’t be someone that’s not clear-headed. That’s where I took a step back. I was like, ‘I’ve got to be someone that’s calm for everybody else, even in situations where it’s hectic.’ And I asked myself, like, ‘OK, how do you calm yourself down?’ That’s helped me a lot.” It’s almost impossible for professional athletes to escape the inherent negativity of the job. Even players who prefer to log off social media struggle to avoid online discourse — friends or family members will send them screenshots of posts, teammates will huddle to argue over a hot take on TV in the locker room. LaVine doesn’t try to avoid the chatter. He keeps an eye on social media, reads and watches analysts and fans alike. He never wants to be caught off guard, always trying to understand the outside world’s perception of him. But LaVine wants to stop worrying about changing that perception. It’s a constant source of conversation with Hunter and his father, Paul. And it’s not easy or perfect. Still, the result has been visible to teammates, even as the Bulls struggle through a 6-10 start . “He’s in a great space and I’m actually proud of him for that,” Dosunmu told the Tribune. “We see it and you can just tell it by watching him. He’s playing great, he’s shooting the ball great, he’s being a great teammate. I’m happy for him.” Some of this is just about growing up. This is the first year LaVine is really beginning to feel his age. Not too much. He turns 30 on March 10. There’s still a buoyant spring in the way he launches toward the rim for a dunk. But it means something to be in Year 11. LaVine is the undisputed veteran leader of the young roster. And sure, he can’t help but laugh when rookie Matas Buzelis — “that bastard,” he joked — calls him an OG, but he also knows it’s a sign of respect that he has worked for years to earn. And for LaVine, only the main difference matters when comparing this year to last: He’s happy. He feels like himself on the court. His family is thriving off it. And whatever comes next — wins, losses, a trade, another season in Chicago — LaVine feels more in control than ever. “I can’t make everybody happy,” LaVine said. “I can’t control if people are wrong or right about their own opinions. I can just go out here and try to continue to do the best I can for myself, my family, my team. I’m being true to myself. That’s a peace in itself.”

It wasn't a great day to be a Commanders' running back. First, it was Brian Robinson Jr. who exited with an ankle injury early in the game, but he later returned. Then it was Austin Ekeler , who appeared to be knocked out at the conclusion of a wild 60 minutes. The Week 12 game against the Cowboys featured lead changes, special teams mayhem and some near-magic for the Commanders . While the comeback effort fell short, dropping Washington to 7-4 on the season, the concern now shifts to Ekeler. Here is the latest on the Commanders' veteran running back. Austin Ekeler injury update Ekeler was helped off the field late in the fourth quarter following a kickoff return with nine seconds to go. NFL STATS CENTRAL: The latest NFL scores, schedules, odds, stats and more. Teammates immediately called to the sidelined for assistance as Ekeler lay on the ground motionless. The running back wasn't given a chance to return since the injury occurred at the end of the game on Sunday. Commanders RB depth chart If Ekeler is forced to miss time, Washington will be down to just two running backs. Robinson Jr. would remain the starting back, but McNichols would likely see more work.

NoneMGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today presented a talk titled “Specific and efficient genome editing with metagenomics-derived tools for in vivo and ex vivo therapeutic applications” at the Nature Conference: RNA at the Bench and Bedside IV. “We believe the value proposition for single-dose gene editing therapies requires exquisite specificity characterization to ensure safety and efficacy. Today’s presentation highlights the precision of Metagenomi’s next-generation nucleases and ABEs, discovered through the company’s proprietary metagenomics platform and tailored for both in vivo and ex vivo therapeutic applications,” said Alan Brooks, SVP and Head of Preclinical. “MGX-001, Metagenomi’s development candidate for hemophilia A, which utilizes the novel nuclease MG29-1, exhibits no identifiable off-target editing using a series of orthogonal assays employed to evaluate potential off-target sites in the genome. The MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes. For Metagenomi’s novel next-generation ABE for ex vivo cell therapy indications via multiplex editing, the data showed no detectable translocations and no significant genomic base composition differences in primary T-cells when compared to unedited cells. These examples demonstrate our strong capabilities in developing highly specific next-generation gene editing tools and support the company’s ability to potentially progress these systems toward the clinic for the benefit of patients.” About Metagenomi Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases (CAST)). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://​metageno​mi​.co. Cautionary Note Regarding Forward‐​Looking Statements This press release contains ​“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as ​“anticipate,” ​“believe,” ​“could,” ​“estimate,” ​“expect,” ​“goal,” ​“intend,” ​“look forward to,” ​“may,” ​“plan,” ​“potential,” ​“predict,” ​“project,” ​“should,” ​“will,” ​“would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in ​“Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Contact: Simon Harnest - CIO, SVP Investor Relations IR@​metagenomi.​co

SAN DIEGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- LPL Financial LLC (“LPL Financial”), a wholly owned subsidiary of LPL Financial Holdings Inc. ( Nasdaq: LPLA ) (the “Company”), today released its monthly activity report for October 2024. Total advisory and brokerage assets at the end of October were $1.67 trillion, an increase of $81.2 billion, or 5.1%, compared to the end of September 2024. Total net new assets for October were $96.6 billion, which included $88.0 billion of acquired net new assets resulting from the acquisition of Atria Wealth Solutions, Inc. (“Atria”) and $0.3 billion of acquired net new assets resulting from Liquidity & Succession activity. Total organic net new assets for October were $8.3 billion, translating to a 6.2% annualized growth rate. This included $1.0 billion of assets that off-boarded as part of the previously disclosed planned separation from misaligned large OSJs. Excluding these assets, organic net new assets were $9.3 billion, translating to a 7.0% annualized growth rate. Total organic net new advisory assets were $8.8 billion, translating to a 11.9% annualized growth rate. Excluding the off-boarded assets from misaligned large OSJs, total organic net new advisory assets were $9.1 billion, translating to a 12.2% annualized growth rate. Total client cash balances at the end of October were $48.3 billion, an increase of $2.5 billion compared to the end of September 2024. This included $2.3 billion resulting from the acquisition of Atria. Net buying in October was $12.5 billion. Note: Totals may not foot due to rounding. (1) During the first quarter of 2024, the Company updated its definition of client cash account balances to exclude other client payables. Prior period disclosures have been updated to reflect this change as applicable. For additional information regarding these and other LPL Financial business metrics, please refer to the Company’s most recent earnings announcement , which is available in the quarterly results section of investor.lpl.com . Contacts Investor Relations investor.relations@lplfinancial.com Media Relations media.relations@lplfinancial.com About LPL Financial LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 28,000 financial advisors and the wealth management practices of approximately 1,200 financial institutions, servicing and custodying approximately $1.7 trillion in brokerage and advisory assets on behalf of approximately 6 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com . Securities and Advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor. Member FINRA/SIPC. LPL Financial and its affiliated companies provide financial services only from the United States. Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial. We routinely disclose information that may be important to shareholders in the “ Investor Relations ” or “ Press Releases ” section of our website.Jon Tetzlaff On the day The Boeing Company ( NYSE: BA ) restarted production on the Boeing 737 MAX program, the US jet maker also posted its order and delivery figures for the month of November. The two news items marked the reality of deliveries If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform. Dhierin-Perkash Bechai is an aerospace, defense and airline analyst. The Aerospace Forum Learn more Analyst’s Disclosure: I/we have a beneficial long position in the shares of BA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The Future of Scottish Cyber Security with Jera ITVancouver police board vice-chair asked to resign after social media rant about 'Christian values'

Ramsey long way off Cardiff return, says boss Riza